- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Capital Research Global Investors Boosts Stake in Biohaven
Institutional investor increases holding in pharmaceutical company by over 100%
Mar. 13, 2026 at 8:20am
Got story updates? Submit your updates here. ›
Capital Research Global Investors, a major institutional investor, has significantly increased its stake in Biohaven Ltd. (NYSE:BHVN), a biopharmaceutical company focused on developing therapies for neurological and neurovascular diseases. According to a regulatory filing, Capital Research Global Investors lifted its position in Biohaven by 108.9% during the third quarter, now owning over 1 million shares or 0.96% of the company.
Why it matters
This substantial increase in ownership by a prominent institutional investor like Capital Research Global Investors suggests growing confidence in Biohaven's pipeline and future prospects. As a clinical-stage biopharma company, Biohaven's performance and valuation are closely watched by the investment community.
The details
Capital Research Global Investors acquired an additional 527,337 shares of Biohaven during the third quarter, bringing its total position to 1,011,530 shares. This represents a 108.9% increase in the firm's stake in the company. Biohaven is developing a portfolio of therapies targeting neurological conditions like migraine, with its lead CGRP receptor antagonist program being closely monitored.
- Capital Research Global Investors disclosed the increased stake in a regulatory filing on March 13, 2026.
The players
Capital Research Global Investors
A major institutional investment management firm that oversees over $2 trillion in assets.
Biohaven Ltd.
A clinical-stage biopharmaceutical company focused on developing therapies for neurological and neurovascular diseases.
The takeaway
This significant increase in ownership by a prominent institutional investor like Capital Research Global Investors underscores the market's growing confidence in Biohaven's pipeline and future potential as a clinical-stage biopharma company.
